<DOC>
	<DOCNO>NCT00268645</DOCNO>
	<brief_summary>The aim project confirm efficacy safety profile Insulin glargine daily practice improve physician ' knowledge experience concern Insulin glargine</brief_summary>
	<brief_title>Insulin Glargine Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patient , Diabetic patient receive insulin patient insulinnaive whose glycemic control sufficiently maintain single combined oral antidiabetic agent , Patients HbA1C &gt; 8 Patients able selfmeasure blood glucose level . According package insert information ( Summary Product Characteristics )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>